OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Nuclear Medicine is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	185
Practicing Medicine in Wartime Ukraine	143
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	120
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	115
Localized In Vivo Prodrug Activation Using Radionuclides	102
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	94
[¹⁷⁷Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial	89
Quantitative Deauville Scoring to Uncover Prognostic Information from ¹⁸F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial	87
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	83
Diagnostic Performance of [ ¹⁸ F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study	76
Serial [ ¹⁸ F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair	74
Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [ ¹⁷⁷ Lu]Lu-PSMA Therapy Injections Through Serial	72
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	68
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	65
Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024)	64
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	62
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	62
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	60
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	59
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	59
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	58
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	57
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	56
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	56
Interspecies Variability in Biodistribution and PET Imaging Performance of [¹⁸F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer	54

State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	54
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	54
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	53
Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics	52
Challenges with¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice	51
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	51
Precision Medicine Clinical Trials	51
Diuresis During¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial	50
¹⁶¹Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with¹⁷⁷Lu in Preclinical Models of Ovarian Cancer	49
High-Resolution Silicon Photomultiplier Time-of-Flight Dedicated Head PET System for Clinical Brain Studies	49
Intrapatient 16α-[¹⁸F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast	49
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology	49
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on¹⁸F-FDG PET/MRI and Machine Learning	49
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer	49
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	48
The Role of Molecular Imaging in Precision Oncology	48
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	48
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection	47
Artificial Intelligence–Powered Quantification of Flortaucipir PET for Detecting Tau Pathology	47
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”	47
¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?	46
Dual-Tracer Imaging on a Long–Axial-Field-of-View PET: A Proof-of-Principle Study with [¹⁸F]FGln and [¹⁸F]FDG	46
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	46
Dual-Time-Point Posttherapy¹⁷⁷Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome	45
Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors	45
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	44
First-in-Human Study of [¹¹C]NCGG401 for Imaging Colony-Stimulating Factor 1 Receptors in the Brain	44
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer	43
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses	43
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer	43
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)	41
Funding Reductions Threaten the Future of Medical Innovation	41
Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer	40
An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients	40
Early-Phase¹⁸F-Florbetapir and¹⁸F-Flutemetamol Images as Proxies of Brain Metabolism in a Memory Clinic Setting	40
Preclinical Evaluation of ⁶⁴ Cu-LNTH-1363S to Detect Cardiac FAP-Positive Fibroblasts Using PET Imaging	40
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	39
Biodistribution, Safety Profile, and Radiation Dosimetry of [¹⁸F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects	39
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	39
Submillimeter-Resolution PET for High-Sensitivity Mouse Brain Imaging	39
Nanoparticle Diagnostics and Theranostics in the Clinic	39
The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice	38
Molecular Imaging, Radiochemistry, and Environmental Pollutants	38
Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study	37
¹⁷⁶Lu Radiation in Long–Axial-Field-of-View PET Scanners: A Nonissue for Patient Safety	37
Feasibility of¹⁷⁷Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer	37
Clinical Validation of Deep Learning for Image Restoration of Ultra-Low-Count [¹⁸F]FDG PET for Dementia Diagnostics	37
Pretargeted Radioimmunotherapy of Ovarian Cancer with²²⁵Ac and an Internalizing Antibody	36
Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA: A Multicenter Retrospective Analysis	36
Is It Too Soon to Know When It’s LATE?	36

Prospective Multicenter Evaluation of [¹¹C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease	36
Tumor Dose–Response Relationship of [¹³¹I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [¹²⁴I]MIBG PET	36
SNMMI/EANM/ASNC/ACNM Procedure Standard/Practice Guideline for ¹⁸F-Flurpiridaz PET Myocardial Perfusion Imaging and Blood Flow Quantitation	36
Influence of Ultra-Low-Dose CT on PET Image Quantification and Visual Assessment	36
CD38-Targeted⁸⁹Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care	35
Automated Brain Tumor Detection and Segmentation for Treatment Response Assessment Using Amino Acid PET	35
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for²²³Ra-Based Radiopharmaceutical Therapies	34
Immuno-PET Detects Antibody–Drug Potency on Coadministration with Statins	33
First-in-Human Study of [²¹¹At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)	33
An External, Independent Validation of anO-(2-[¹⁸F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma	33
Progression or Response: New Liver Lesions in a Patient with Responding Hodgkin Lymphoma	33
Thyroid Hormone Withdrawal Yields Higher ¹³¹ I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a L	33
Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council	33
Evaluating Bone Healing with [¹⁸F]NaF PET/CT During Bone Segment Transport in Femoral Fracture Treatment	32
First-in-Human Evaluation of Site-Specifically Labeled⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer	32
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins	32
Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET	32
Comparison of Baseline⁶⁸Ga-FAPI and¹⁸F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibit	32
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy	32
MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling	32
First Safety and Efficacy Data with the Radiohybrid¹⁷⁷Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer	32
First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using¹⁸F-labeled Active-Site Inhibited Factor VII (¹⁸F-ASIS): Potential as Companion	32
Arrhythmias in Nongranulomatous Myocarditis: Is There a Role for PET?	31
Tau PET Imaging in Neurodegenerative Disorders	31
Molecular Imaging in Breast Cancer	31
Green Nuclear Medicine and Radiotheranostics	31
Potential of¹⁸⁸Re as an Alternative to¹⁷⁷Lu and Dosimetric Consequences	31
Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma	31
Identification of (R)-[¹⁸F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development	30
Posterior Cingulate Involvement Does Not Argue Against LATE	30
[²²⁵Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and Kidneys	30
Quantitative [⁸⁹Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI	30
The Rise of Molecular Image–Guided Robotic Surgery	30
Histologic Ex Vivo Validation of the [¹⁸F]SITATE Somatostatin Receptor PET Tracer	30
Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies?	30
Tau PET Visual Reads: Research and Clinical Applications and Future Directions	30
Histology-Based Radiomics for [¹⁸F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer	29
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients	29
Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer	29
First-in-Human Study of¹⁸F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding	29
High-Resolution Positronium Lifetime Tomography at Clinical Activity Levels on the PennPET Explorer	29
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior²²³Ra (RALU Study)	29
Total Body PET – Will it Change Science and Practice?	29
The Imperative for Comparative Studies in Nuclear Medicine: Elevating¹⁷⁷Lu-PSMA-617 in the Treatment Paradigm for mCRPC	29
Diagnostic Potential of Supplemental Static and Dynamic⁶⁸Ga-FAPI-46 PET for Primary¹⁸F-FDG–Negative Pulmonary Lesions	29
¹⁶¹Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas	29
Quantitative Brain Amyloid PET	29
How Many Theranostics Centers Will We Need in the United States?	28
[⁶⁸Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis	28
Not All Gatekeepers Are Theranostics	28
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective	28
Efficacy, Safety, Blood Kinetics, and ²¹³Bi Distribution Studies of [²²⁵Ac]Ac-SibuDAB in Prostate Cancer Patients	28
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study	28
Differential Effects of Tau Stage, Lewy Body Pathology, and Substantia Nigra Degeneration on¹⁸F-FDG PET Patterns in Clinical Alzheimer Disease	28
MIRD Pamphlet No. 29: MIRDy90—A⁹⁰Y Research Microsphere Dosimetry Tool	28
⁶⁸Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study	28
High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections	28
MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy	28
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis	28
Amino Acid PET in Neurooncology	27
CD70-Targeted [¹⁸F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study	27
Preirradiation of Spheroids with ²²⁵Ac-Trastuzumab Improves Penetration of ²²⁵Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails	27
A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy	27
BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of ²²⁵ Ac-GPC3 (BAY 3547926) in Patients with Advanc	27
Distinguishing Progression from Pseudoprogression in Glioblastoma Using¹⁸F-Fluciclovine PET	27
Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma	27
Delayed Imaging Improves Lesion Detectability in [^99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer	26
China’s Innovations in Nuclear Medicine: Global Insights into Clinical Advancements and Impact	26
Utility of⁶⁴Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on⁶⁸Ga-PSMA-11 PET/CT	26
Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [¹⁸F]FDG PET/CT and¹³¹I Posttreatment Scanning	26
Evaluating Radiotheranostic Targets for Endometrial Cancer	26
Detecting CXCR4 Expression in Meningioma on⁶⁸Ga-Pentixafor PET/MRI	26
⁶⁴Cu-DOTA Enables Late PET Imaging and Leak Detection in the Cerebrospinal Fluid Space	25
Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent	25
[¹⁸F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy	25
A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides	25
Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose	25
Association of Free-to-Total PSA Ratio and¹⁸F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Si	25
¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy	25
Summary of the 2024 Update of the North American Guidelines for Pediatric Administered Radiopharmaceutical Activities	25

Automated Total-Body Perfusion Imaging with ¹⁵O-Water PET Using Basis Functions and Organ-Specific Model Selection	25
Imaging Efficacy of [¹⁸F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study	25
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas	24
Advancing Nuclear Medicine at the Multiomics Intersection	24
Future Directions in Molecular Imaging of Neurodegenerative Disorders	24
Stakeholders of Theranostics	24
Theranostics in Perspective: White Paper	24
Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy	24
Redefining Nuclear Medicine: “Biodistribution” Should Be the Core Concept	24
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy	24
¹⁸F-AlF-NOTA-Octreotide Outperforms⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study	24
Design, Preclinical Evaluation, and Clinical Translation of⁶⁸Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma	24
Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists	24
Recent Evidence on Cardiac^99mTc-DPD Uptake After Therapy with Tafamidis May Reveal the Road to an Ultra-Early Diagnosis in Patients with ATTR Amyloidosis	23
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET	23
[ ⁶⁸ Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[ ¹⁸	23
[⁶⁸Ga]Ga-PSMA-11 PET and Prostate Cancer Bone Metastases: Diagnostic Performance of Available Standardized Criteria	23
Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW	23
⁶⁸Ga-FAPI-04 PET/CT in Non–Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression	22
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with¹⁶¹Tb and¹⁷⁷Lu: A Comparative Study	22
Perspective on Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery	22
FAPI PET/CT Immune-Fibrosis Imaging for New Insights into Rheumatologic Disorders	22
Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer	22
Safety and Survival Outcomes of¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior²²³Ra treatment: The RA	22
Dosimetry of [¹⁷⁷Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial	22
The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?	22
^99mTc-MIP-1404 SPECT/CT Companion Diagnostic for¹⁷⁷Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer	22
Increased Metabolic Activity of the Thymus and Lymph Nodes in Pediatric Oncology Patients After Coronavirus Disease 2019 Vaccination	22
Theranostic Digital Twins: An Indispensable Prerequisite for Personalized Cancer Care	22
Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy	22
MIRD Pamphlet No. 31: MIRDcell V4—Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy	22
Safety, Dosimetry, and Feasibility of [⁶⁸Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer	22
Total-Body ¹⁸F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations	22
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy	22
Tracking Innate Immune Activation in a Mouse Model of Parkinson’s Disease Using TREM1 and TSPO PET Tracers	22
The Emission of Internal Conversion Electrons Rather Than Auger Electrons Increased the Nucleus-Absorbed Dose for¹⁶¹Tb Compared with¹⁷⁷Lu with a Higher Dose Response for [¹⁶	22
Antihormonal-Treatment Status Affects⁶⁸Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer	21
Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis	21
Effect of Acute Hypoxia Exposure on the Availability of A₁Adenosine Receptors and Perfusion in the Human Brain	21
α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer	21
Advancing Tomorrow’s Cancer Medicines	21
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸F-rhPSMA-7.3 PET/CT in patients with prostate cancer	21
¹⁸F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors	21
A New Dawn	21
[¹⁸F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lu	21
Reply: Dosimetry in Radiopharmaceutical Therapy	21
First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [⁶⁸Ga]Ga-BCY25286	21
Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy	21
Evaluation of Mitochondrial Complex 1 Density with [¹⁸F]BCPP-EF in a Murine Model and Individuals with Friedreich Ataxia	21
Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma	21
Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with ¹⁷⁷ Lu-PSMA: A Retrospective, Single-Cent	20
Changes in Management After ¹⁸F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes	20
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up	20
First-in-Human Study of¹⁸F-Labeled PET Tracer for Glutamate AMPA Receptor [¹⁸F]K-40: A Derivative of [¹¹C]K-2	20
Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic¹⁸F-FDG PET Kinetic Modeling	20
Differences in Fibroinflammatory Activity Shown on⁶⁸Ga-FAPI-04 and¹⁸F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease	20
Preclinical Investigation of [²¹²Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model	20
[ ¹¹ C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study	20
Virtual Biopsy: Just an AI Software or a Medical Procedure?	20
Carotid Artery Image-Derived Blood Time–Activity Curves on the NeuroEXPLORER: Initial Multitracer Validation Against Arterial Sampling	20
⁶¹Cu-Labeled Radiotracers: Alternative or Choice?	20
SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy	20
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer	20
A Timeline of Multimodality Imaging	20
Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview	20
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)	19
Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial	19
Immunohistochemical FAP Expression Reflects⁶⁸Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma	19
Advancing Clinical Trial Innovation in Pancreatic Cancer	19
PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy	19
Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies	19
First-in-Human Study of the Carbohydrate Nanoparticle ⁶⁴ Cu-Macrin	19
SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury	19
Advancing Nuclear Medicine in Australia over 3 Decades	19
Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy	19
ChatGPT: Can You Prepare My Patients for [¹⁸F]FDG PET/CT and Explain My Reports?	19
Nuclear Cardiology Surrogate Biomarkers in Clinical Trials	19
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard	19
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE	19
Imaging of the Aging Human Brain	18
Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease	18
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer	18
From Scientist to Analyst to Strategist	18
Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention	18
Exploring Vessel Wall Biology In Vivo by Ultrasensitive Total-Body PET	18
Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI	18
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [ ¹⁸ F]MK6240 Tau PET in Target Regions	18
Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using¹¹C-Acetate PET	18
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using¹⁸F-FDG PET	18
Multicentric Matched-Pair Analysis of Long-Term Hematotoxicity of Peptide Receptor Radionuclide Therapy in Patients Postsplenectomy	18
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data	18
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma	18
2024 SNMMI Highlights Lecture: General Clinical Specialties	18
The Future of Nuclear Medicine in the United States	18
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma	18